ALK and non-small cell lung carcinoma: To independently test this observation with our own data, WES was performed on paired pre- and post-TKI treated samples obtained from 32 patients (Supplementary Table 4) to quantify mutations acquired following TKI treatment in NSCLC EGFRmut (treated with erlotinib/osimertinib) and ALK fusion (treated with alectinib) clinical samples.